Yiling Pharmaceutical once again responded to the question and Yiling Pharmaceutical opened at a limit. In the news, Yiling Pharmaceutical previously said that the company had never said on any occasion that "WHO recommended Lianhua Qingpancreatic". Yiling Pharmaceutical once again responded to the question and Yiling Pharmaceutical opened at a limit.
Yiling Pharmaceutical responded to the inquiry, and Yiling Pharmaceutical opened at a limit of 1. Following the limit 15 in April, Yiling Pharmaceutical (002603) continued to open at the limit 18 in April, and its current share price is 32.39 yuan/share.
In the news, on April 17, Dr. Lilac published a paper entitled "Don't eat lotus flowers to clear the plague and prevent COVID-19" in his official Weibo, which was screened online for a period of time.
Prevent COVID-19 from not eating lotus flowers to clear the plague.
Where is the future growth point of Yiling Pharmaceutical torn by Wang Sicong?
At noon on April 14, 2022, Wang Sicong forwarded a message in Weibo about questioning whether Lianhua Qingwen was recommended by WHO, and wrote that "CSRC strictly investigated Yiling Pharmaceutical".
Although Weibo was released an hour later, Wang Sicong took the initiative to delete the above remarks, but with the fermentation of public opinion, on April 15, Yiling Pharmaceutical, the main operator of Lianhua Qingwen, still hit the daily limit, with a closing price of 35.99 yuan/share, a decrease of 10%, and the market value of that day evaporated by 6.7 billion yuan.
In response to Wang Sicong's query, on the afternoon of April 14, the staff of Yiling Pharmaceutical Securities Department told Yin Shi Finance, "Please point out the specific problems and sources about the news spread in Weibo. You can't ask questions at will because of the word Wang Sicong. "
Perhaps it is because such a reply did not stop the stock price from falling. On April 16, the official of Yiling Pharmaceutical once again stood up and said to China Entrepreneur: "The company has never said on any occasion that' WHO recommended Lianhua Qingwen'".
Yiling Pharmaceutical once again responded to the question. Yiling Pharmaceutical Co., Ltd. opened at a daily limit of 18 in April, and Yiling Pharmaceutical Co., Ltd. (002603) closed at a daily limit of 65,438+10,000 lots, which has closed the board for two consecutive days.
In the news, Yiling Pharmaceutical previously said that the company had never said on any occasion that "WHO recommended Lianhua Qingpancreatic".
According to the Securities Times, on April 6th 13: 08, Wang Sicong forwarded a message about Lianhua Qingwen Capsule in Weibo, saying that the regulatory authorities should strictly investigate Yiling Pharmaceutical. This remark quickly fermented on the Internet.
In response to online comments, Yiling Pharmaceutical quickly responded positively, saying, "Regarding the news spread in Weibo, please point out the specific questions and sources, and we will answer the specific contents. We have complete evidence and report disclosure from clinical trials, specific experimental data, and the diagnosis and treatment plan included in COVID-19, including indications and instructions. You can't ask questions just because of the word' Wang Sicong'. I just listened to some comments on the internet. Investors please screen. "
About an hour later, Wang Sicong edited the Weibo and deleted the words that the regulatory authorities should strictly investigate Yiling Pharmaceutical.
"Securities Times" reported that since the outbreak of the new crown, Lianhua Qingwen, as a medicine, has shined brilliantly in COVID-19. On April 14, the share price of Lianhua Qingwen Capsule manufacturer and A-share listed company Yiling Pharmaceutical also closed at the daily limit, with a turnover rate of 10.5 1% and a turnover of 559 1 100 million yuan.
Since the beginning of this year, the share price of Yiling Pharmaceutical has risen by as much as 1.20%. At present, the latest market value is 54 1 100 million yuan, and the increase this year is still as high as 65%.
According to market analysis, Yiling Pharmaceutical, as the core listed company of proprietary Chinese medicines, has been held by many institutions. As of February 20021,65438+,3 1, * * * 65 fund institutions held 48.2679 million shares. Among them, Industrial Global Fund * * 4 products hold 8,444,700 shares, southern fund * * 9 products hold 6,524,200 shares of Yiling Pharmaceutical, and Huaan Fund 10 products hold 4,565,438+0,900 shares.
In terms of specific products, Xingquan Hexing, managed by well-known fund managers, held 2,386,300 shares after two years of closed operation, Huaan Ecological Optimization, managed by Chen Yuan, held1843,900 shares, and Southern Baofeng, managed by Lin Lefeng and Sun, held 65,438+10,000 shares.
As of April 18, Yiling Pharmaceutical's share price was 32.39 yuan, down 10.00%.
Yiling Pharmaceutical once again responded to the inquiry, and Yiling Pharmaceutical opened its daily limit 18 on April 3, and Yiling Pharmaceutical fell for two consecutive days. As of press time, Yiling Pharmaceutical's share price was 32.39 yuan/share, the turnover rate was 0.77%, and more than 280,000 lots were sold, with a total market value of 54 1 100 million yuan.
On June 4th, 65438, Wang Sicong forwarded a video questioning whether the World Health Organization recommended Lianhua Qingwen Capsule. Affected by the incident, the share price of Yiling Pharmaceutical 15 fell to 35.99 yuan/share.
In response to online comments, Yiling Pharmaceutical responded: "The company has never said' who recommended Lianhua Qingwen' on any occasion".
According to media reports, recently, a number of websites have been "WHO recognized the efficacy of traditional Chinese medicine in treating COVID-19 and the prevention and treatment of blooming flowers" and "WHO recognized! Lianhua Qingwen contributed "China wisdom" to the global war and epidemic situation. "Chinese medicine has shown great power in fighting the epidemic situation, and WHO has proved it to be safe and effective, which is recommended to member countries". The source of these articles points to the Report of the WHO Expert Evaluation Meeting on Chinese Medicine Treatment in COVID-19, which was released at the World Health Organization meeting in official website on March 3 1.
The report was published by WHO on the official website on March 3 1. According to the report, Dr. Yu, director of China state administration of traditional chinese medicine, said at the meeting that the prevention and treatment of-19 by traditional Chinese medicine is an important factor to keep the course of China low.
In state administration of traditional chinese medicine, Dr. Yu said that during the Wuhan epidemic, state administration of traditional chinese medicine (China) approved the sale of three kinds of traditional Chinese medicines through special approval procedures, and said that the State Administration of Pharmaceutical Products would continue to optimize the diagnosis and treatment scheme of traditional Chinese medicines in an attempt to explain the treatment mechanism scientifically. In addition, it is pointed out in the report that Chinese medicine can effectively treat COVID-19, reduce the conversion from mild cases and ordinary cases to severe cases, shorten the time for virus clearance, and improve the clinical prognosis of patients with mild cases and ordinary COVID-19. However, the report only mentioned Lianhua's eradication of plague when quoting materials.
It is worth noting that in the past weekend, an article "Don't eat lotus flowers to clear the plague and prevent COVID-19" published by Dr. V "Clove Doctor", a doctor of Internet medicine, was screened online. In his article, Dr. Lilac publicly stated that even if the flowers were used to clear the plague, COVID-19 could not be prevented, and called on people not to take medicine indiscriminately without getting sick, even if the flowers were used to clear the plague.
The above article also quoted the definition of disease prevention from the World Health Organization, saying that under the current scientific conditions, people can use the following three measures to prevent COVID-19: physical blocking, inducing immune response and pre-exposure prevention, and pointed out that among the three known methods, even COVID-19 cannot be prevented.
In March this year, Yiling Pharmaceutical pointed out in the prompt announcement of "Lianhua Qingwen Capsule (Granule) Incorporated into novel coronavirus's Diagnosis and Treatment Plan (Trial Ninth Edition)" that in the first three quarters of 20021year, Lianhua Qingwen products realized an operating income of 3.37 billion yuan, accounting for 4 1.6% of the total operating income.